Firm has a library of peptides sourced from nonhuman biological genomes.

Phylogica plans on using Aegis Therapeutics’ Intravail® transmucosal delivery formulations with its peptide drug candidates. The companies will offer their services to parties seeking an intranasal peptide developed against their target of interest.

Phylogica has a peptide library called Phylomer. These peptides are sourced from nonhuman biological genomes. This enhances their potency against human protein targets, according to Phylogica. Also, since the typical size of a Phylomer ranges from 15 to 50 amino acids, they do not trigger immunogenicity issues, the firm adds.

“Phylomer peptides are of an ideal size to deliver as a nasal spray using the Intravail formulation, since they are much smaller than proteins such as antibodies, which are delivered far less efficiently by means other than injection,” notes Phylogica’s CSO and vp of corporate development, Paul Watt, D. Phil.

“Peptides of the size of many of our Phylomers have been delivered with bio-availabilities of 80%,” Dr. Watt continues. “This is very impressive and suggests that intranasal delivery of Phylomers may be highly feasible.”

Previous articleStimulus Package for VCs Supporting Small Biotechs
Next articleMerck & Co. Gains Rights to Santen’s Glaucoma Drug in the Americas, W. Europe, and Africa